Stifel raises Edwards Lifesciences stock to buy, target to $90
Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also ...
Edwards Lifesciences upgraded to Buy from Hold at Stifel
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...
Health Rounds: Mechanical aortic valves may be preferable in younger patients needing replacement
Middle-aged adults who need an aortic valve replacement fare better with mechanical devices than with the valves made from animal tissues that they currently most often receive, U.S. researchers ...
Mechanical valves offer superior long-term survival for aortic valve replacement patients aged 60, study finds
Annual Meeting reveals that mechanical aortic valve replacements (AVRs) provide significant long-term survival benefits for ...
Caranx Medical submits AI TAVI-TAVR guide software to FDA
TAVIPILOT Soft is said to be a ‘world-first’ provision for real-time surgical guidance during TAVI and TAVR procedures.
Business Wire5d
EDWARDS LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Li…
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”) ...
MassDevice7d
Analysts expect JenaValve TAVR approval for aortic regurgitation in 2025
GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...
Do You Believe in the Growth Prospects of Edwards Lifesciences Corporation (EW)?
Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...
Edwards Lifesciences downgraded at Wolfe on TAVR worries
Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.
Edwards Lifesciences downgraded to Underperform at Wolfe Research
Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...
The New England Journal of Medicine16d
Giant-Cell Aortitis Causing an Aneurysm of the Ascending Aorta and Aortic Regurgitation
There was free aortic regurgitation because of dilatation of the valvular annulus; the cusps themselves were not deformed. The valve was excised and a No. 9 Starr-Edwards valve inserted.